"The Mechanic" Cellular Energy Optimization Protocol

Your cells run on a molecule called ATP, which is what your body actually uses when it contracts a muscle, fires a neuron, or repairs a tissue. Almost all of it gets made inside your mitochondria through a process that works like a carefully managed assembly line, and when that assembly line starts breaking down, you feel it long before any test can confirm it.

The breakdown happens in three places at once as you age. First, the inner mitochondrial membrane develops structural damage that causes the electron transport chain to leak energy instead of capturing it. Second, a protein called CD38, which is an enzyme that destroys NAD+, gets activated by senescent cells and strips the raw material your mitochondria need to run the assembly line. Third, the machinery itself becomes less efficient, requiring more input to produce the same output.

Understanding those three failure points tells you exactly why the protocol is sequenced the way it is. You cannot optimize a broken system. Repair has to come before enhancement, and the foundation has to exist before either one.

So the foundation is first because micronutrients and basic supplements fill the gaps that make the rest of the protocol possible. Magnesium is required for over 300 enzymatic reactions including ATP synthesis itself. CoQ10 carries electrons between Complex I and Complex III in the electron transport chain, and there is a meaningful decline in CoQ10 status with age. Creatine at five grams per day saturates the phosphocreatine system, which acts as an immediate ATP buffer so your cells do not have to spin up full mitochondrial production for every small demand. Without these inputs, the more targeted compounds have less to work with.

Then comes repair, and this is where the sequencing starts to matter more precisely.

SS-31, which is sometimes called elamipretide, is a small peptide that selectively binds something called cardiolipin, which is a specialized phospholipid embedded in the inner mitochondrial membrane and responsible for anchoring the proteins of the electron transport chain in their correct positions. When cardiolipin is damaged or oxidized, those proteins shift, the chain develops gaps, and electrons leak out as heat and reactive oxygen species instead of driving ATP production. The 2013 Birk study showed that SS-31 re-energizes ischemic mitochondria specifically through this cardiolipin interaction, stabilizing the membrane structure and reducing that electron leakage. The dose in the protocol is 1 to 2 milligrams per day for four to eight weeks, which is conservative relative to what some research has used, and conservative here is the right call because you are working on the structural integrity of your membrane before layering anything else on top.

Once the membrane is stabilized, FOXO4-DRI addresses the second failure point, which is senescent cell accumulation. Senescent cells are cells that have stopped dividing but refuse to die, and they drive NAD+ decline through a mechanism that works in two steps. The senescent cells release inflammatory signals called SASP cytokines, which recruit macrophages, and those macrophages upregulate CD38. The 2020 Covarrubias study established this causal chain directly, and the 2016 Camacho-Pereira study found that CD38 activity increases two to three fold with age while CD38 knockout mice maintained their NAD+ levels across their entire lifespan. What that means is that supplementing NAD+ precursors without addressing the senescent cells driving CD38 is like filling a bathtub with the drain open.

FOXO4-DRI interrupts a survival signal inside senescent cells. Normally a protein called FOXO4 binds to p53 and holds it away from the mitochondria, preventing the cell from triggering its own death even when it should. FOXO4-DRI disrupts that interaction, freeing p53 to do its job. The Baar 2017 study showed 11.73-fold selectivity for senescent cells over healthy cells, which is the number that justifies using it at all. The three-dose protocol over roughly a week is enough to clear a meaningful senescent load, and the immune response during that clearance is why some people feel off for a few days. That is not a side effect to suppress. It is the process working.

Epithalon at 500 micrograms to one milligram per day for 10 to 20 days, done one to two times per year, works through a different mechanism. It induces expression of hTERT, which is the catalytic component of telomerase, the enzyme that maintains telomere length at the ends of chromosomes. The 2003 Khavinson study confirmed this in human fibroblasts. Telomere erosion is one of the upstream signals that pushes cells toward senescence in the first place, so Epithalon is addressing a cause of the problem that FOXO4-DRI addresses the consequence of.

After the repair phase, the transition to MOTS-c is where the architecture of the whole protocol clicks into place. MOTS-c is a peptide encoded in the mitochondrial genome itself, and it activates something called AMPK, which is essentially the cell's master energy sensor and regulator. The 2015 Lee study showed MOTS-c prevented diet-induced insulin resistance and obesity in mice through this AMPK activation pathway. When AMPK is engaged, the cell shifts into a higher-efficiency metabolic state, prioritizing mitochondrial function and clearing cellular debris. The reason MOTS-c comes after repair rather than before is that AMPK activation pushes your mitochondria to perform at a higher level, and mitochondria with damaged cardiolipin and a depleted NAD+ pool from CD38 activity cannot respond to that signal the way repaired mitochondria can. You need the structure intact before you apply the pressure.

On the NAD+ question specifically: most oral NMN and NR is converted by gut bacteria to niacin pathway metabolites before it ever reaches your cells anyway. The 2025 Kim study confirmed that the majority of oral NMN and NR travels through the enterohepatic circulation as niacin-pathway compounds. Niacin accomplishes the same endpoint at a fraction of the cost, which is why it is the recommendation here.

L-carnitine as an optional add-on is mechanistically clean. It is the only molecule that carries long-chain fatty acids across the inner mitochondrial membrane for beta-oxidation, and if you have repaired that membrane with SS-31, having adequate carnitine available means your mitochondria can actually access fat as fuel the way they are now structured to do.

What the entire protocol reflects is a single principle that most supplementation approaches ignore entirely: the bottleneck is not missing molecules, it is structural and cellular damage that makes those molecules impossible to use efficiently. Once the structure is repaired and the senescent load is reduced, the optimization layer works because the infrastructure can now respond to it.

The biggest shift most people notice is not during the repair phase. It is when MOTS-c is added to mitochondria that have already been stabilized, and those mitochondria finally have the capacity to meet the demand being placed on them. That response was always there. The damage was just getting in the way.

---

References

1. Birk AV, Liu S, Soong Y, et al. The Mitochondrial-Targeted Compound SS-31 Re-Energizes Ischemic Mitochondria by Interacting with Cardiolipin. Journal of the American Society of Nephrology. 2013;248:1250-1261. Finding: SS-31 selectively binds cardiolipin on the inner mitochondrial membrane, stabilizing cristae structure. Source
2. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology. 2014;1718:2029-2050. Finding: SS-31 binds cardiolipin, stabilizes mitochondrial membrane structure, and reduces electron leakage and ROS production. Source
3. Baar MP, Brandt RMC, Putavet DA, et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017;1691:132-147. Finding: FOXO4-DRI disrupts FOXO4-p53 interaction in senescent cells, freeing p53 to trigger apoptosis. 11.73-fold selectivity for senescent vs healthy cells. Source
4. Camacho-Pereira J, Tarrago MG, Chini CCS, et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metabolism. 2016;236:1127-1139. Finding: CD38 activity increases 2-3 fold with age. CD38 knockout mice maintained NAD+ levels at all ages. Source
5. Covarrubias AJ, Kale A, Perrone R, et al. Senescent cells promote tissue NAD+ decline during ageing via the activation of CD38+ macrophages. Nature Metabolism. 2020;211:1265-1283. Finding: Senescent cell SASP cytokines induce macrophages to upregulate CD38, establishing the causal chain from senescence to NAD+ decline. Source
6. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003;1356:590-592. Finding: Epithalon induced hTERT expression, telomerase activity, and telomere elongation in human fibroblasts. Source
7. Goncharova ND, Vengerin AA, Khavinson VKh, Lapin BA. Pineal peptides restore the age-related disturbances in hormonal functions of the pineal gland and the pancreas. Experimental Gerontology. 2005;401-2:51-57. Finding: Epithalamin at 5mg/day and synthetic Epithalon at 10mcg/day achieved equivalent melatonin restoration in aged monkeys, demonstrating 500-fold potency difference. Source
8. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;213:443-454. Finding: MOTS-c activates AMPK via inhibition of the folate cycle. Prevented insulin resistance and diet-induced obesity. Source
9. Shats I, Williams JG, Liu J, et al. Bacteria Boost Mammalian Host NAD Metabolism by Engaging the Deamidated Biosynthesis Pathway. Cell Metabolism. 2020;313:564-579. Finding: Gut bacteria deamidate nicotinamide to nicotinic acid niacin, confirming NMN/NR undergo gut conversion before absorption. Source
10. Kim LJ, et al. Nicotinamide riboside and nicotinamide mononucleotide facilitate NAD+ synthesis via enterohepatic circulation. Science Advances. 2025. Finding: Most oral NMN and NR is converted to niacin-pathway metabolites in the gut before absorption. Source
11. Costford SR, Bajpeyi S, Pasarica M, et al. Skeletal muscle NAMPT is induced by exercise in humans. American Journal of Physiology - Endocrinology and Metabolism. 2010;2981:E117-E126. Finding: NAMPT protein increased 127% in sedentary subjects after exercise training. Source
12. Longo N, Frigeni M, Pasquali M. Carnitine transport and fatty acid oxidation. Biochimica et Biophysica Acta. 2016;186310:2422-2435. Finding: L-carnitine is the sole molecule carrying long-chain fatty acids across the inner mitochondrial membrane for beta-oxidation. Source
13. Banerjee R, Purhonen J, Bhardwaj R, Bhargava A, Kallijarvi J. The mitochondrial coenzyme Q junction and complex III. The FEBS Journal. 2022;28922:6936-6958. Finding: CoQ serves as the mobile electron carrier between Complex I/II and Complex III. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness